{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:17:02Z","timestamp":1774473422500,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM138552"],"award-info":[{"award-number":["GM138552"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The rapid mutations of viruses such as SARS-CoV-2 require vaccine updates and the development of novel antiviral drugs. This article presents an improved database filtering technology for a more effective design of novel antiviral agents. Different from the previous approach, where the most probable parameters were obtained stepwise from the antimicrobial peptide database, we found it possible to accelerate the design process by deriving multiple parameters in a single step during the peptide amino acid analysis. The resulting peptide DFTavP1 displays the ability to inhibit Ebola virus. A deviation from the most probable peptide parameters reduces antiviral activity. The designed peptides appear to block viral entry. In addition, the amino acid signature provides a clue to peptide engineering to gain cell selectivity. Like human cathelicidin LL-37, our engineered peptide DDIP1 inhibits both Ebola and SARS-CoV-2 viruses. These peptides, with broad antiviral activity, may selectively disrupt viral envelopes and offer the lasting efficacy required to treat various RNA viruses, including their emerging mutants.<\/jats:p>","DOI":"10.3390\/ph15050521","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T02:22:02Z","timestamp":1650766922000},"page":"521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses"],"prefix":"10.3390","volume":"15","author":[{"given":"Thomas","family":"Ripperda","sequence":"first","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangsheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3689-6104","authenticated-orcid":false,"given":"Elizabeth","family":"Klug","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michellie","family":"Thurman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St Patrick","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-7927","authenticated-orcid":false,"given":"Guangshun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"key":"ref_1","unstructured":"(2022, March 21). WHO Website. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hec.4150","article-title":"The impact of the Ebola crisis on mortality and welfare in Liberia","volume":"29","year":"2020","journal-title":"Health Econ."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shimizu, K., Checchi, F., and Warsame, A. (2022). Disparities in Health Financing Allocation among Infectious Diseases in Ebola Virus Disease (EVD)-Affected Countries, 2005\u20132017. Healthcare, 10.","DOI":"10.3390\/healthcare10020179"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.4314\/ahs.v21i4.11","article-title":"Immunization against severe acute respiratory syndrome Coronavirus 2: An overview","volume":"21","year":"2021","journal-title":"Afr. Health Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-78787-5_18","article-title":"Ebola Virus Disease and Current Therapeutic Strategies: A Review","volume":"1339","author":"Diakou","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 Vaccine Pipeline: An Overview","volume":"7","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lechmere, T., Snell, L.B., Graham, C., Seow, J., Shalim, Z.A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., and Edgeworth, J.D. (2022). Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. Mbio, e0379821.","DOI":"10.1101\/2021.12.01.21266982"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2796.2003.01228.x","article-title":"Antibacterial peptides: Basic facts and emerging concepts","volume":"254","author":"Boman","year":"2003","journal-title":"J. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Etayash, H., and Hancock, R.E.W. (2021). Host Defense Peptide-Mimicking Polymers and Polymeric-Brush-Tethered Host Defense Peptides: Recent Developments, Limitations, and Potential Success. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111820"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000354681","article-title":"Innate immune functions of \u03b1-defensins in the small intestine","volume":"31","author":"Bevins","year":"2013","journal-title":"Dig. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mammari, N., Krier, Y., Albert, Q., Devocelle, M., and Varbanov, M. (2021). On Behalf of the Oemonom. Plant-Derived Antimicrobial Peptides as Potential Antiviral Agents in Systemic Viral Infections. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080774"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2174\/0929867326666190805151654","article-title":"Antiviral Activities of Human Host Defense Peptides","volume":"27","author":"Brice","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1389201020666191011121722","article-title":"Antimicrobial Peptides: A Promising Avenue for Human Healthcare","volume":"21","author":"Bhopale","year":"2020","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00018-021-04030-2","article-title":"Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: An unprecedented property of antimicrobial peptides","volume":"79","author":"Ferrera","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Xu, C., Wang, A., Marin, M., Honnen, W., Ramasamy, S., Porter, E., Subbian, S., Pinter, A., Melikyan, G.B., and Lu, W. (2021). Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses, 13.","DOI":"10.3390\/v13071246"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acsinfecdis.1c00096","article-title":"Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone","volume":"7","author":"Wang","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104930","DOI":"10.1016\/j.micpath.2021.104930","article-title":"Promising role of defensins peptides as therapeutics to combat against viral infection","volume":"155","author":"Solanki","year":"2021","journal-title":"Microb. Pathog."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1007\/s00018-021-03759-0","article-title":"Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs)","volume":"78","author":"Fu","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fmicb.2020.01155","article-title":"Antiviral and Immunomodulatory Properties of Antimicrobial Peptides Produced by Human Keratinocytes","volume":"11","author":"Chessa","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2741\/s83","article-title":"Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense","volume":"2","author":"Hartshorn","year":"2010","journal-title":"Front. Biosci (Schol. Ed.)"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Laneri, S., Brancaccio, M., Mennitti, C., De Biasi, M.G., Pero, M.E., Pisanelli, G., Scudiero, O., and Pero, R. (2021). Antimicrobial Peptides and Physical Activity: A Great Hope against COVID 19. Microorganisms, 9.","DOI":"10.3390\/microorganisms9071415"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rani, P., Kapoor, B., Gulati, M., Atanasov, A.G., Alzahrani, Q., and Gupta, R. (2022). Antimicrobial peptides: A plausible approach for COVID-19 treatment. Expert Opin. Drug Discov., in press.","DOI":"10.1080\/17460441.2022.2050693"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1038\/s41598-022-07341-x","article-title":"Gramicidin S and melittin: Potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection","volume":"12","author":"Enayathullah","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100999","DOI":"10.1016\/j.isci.2020.100999","article-title":"Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection","volume":"23","author":"Yu","year":"2020","journal-title":"Iscience"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"D933-7","DOI":"10.1093\/nar\/gkn823","article-title":"APD2: The updated antimicrobial peptide database and its application in peptide design","volume":"37","author":"Wang","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-2836(82)90515-0","article-title":"A simple method for displaying the hydropathic character of a protein","volume":"157","author":"Kyte","year":"1982","journal-title":"J. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/ph6060728","article-title":"Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs","volume":"6","author":"Wang","year":"2013","journal-title":"Pharmaceuticals"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12426","DOI":"10.1021\/ja305644e","article-title":"Ab initio design of potent anti-MRSA peptides based on database filtering technology","volume":"134","author":"Mishra","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.286.5439.498","article-title":"A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins","volume":"286","author":"Tang","year":"1999","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1128\/AAC.01448-09","article-title":"Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"628585","DOI":"10.3389\/fmolb.2021.628585","article-title":"Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2","volume":"8","author":"Mahmud","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1128\/AAC.00452-08","article-title":"Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins","volume":"52","author":"Wang","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.peptides.2011.04.017","article-title":"Effects of cathelicidin and its fragments on three key enzymes of HIV-1","volume":"2","author":"Wong","year":"2011","journal-title":"Peptides"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"19446","DOI":"10.1073\/pnas.2005540117","article-title":"Two distinct amphipathic peptide antibiotics with systemic efficacy","volume":"117","author":"Mishra","year":"2020","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19260","DOI":"10.1038\/s41598-020-76161-8","article-title":"Better understanding and prediction of antiviral peptides through primary and secondary structure feature importance","volume":"10","author":"Chowdhury","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, C., Sutherland, D., Hammond, S.A., Yang, C., Taho, F., Bergman, L., Houston, S., Warren, R.L., Wong, T., and Hoang, L.M.N. (2022). AMPlify: Attentive deep learning model for discovery of novel antimicrobial peptides effective against WHO priority pathogens. BMC Genom., 23.","DOI":"10.1186\/s12864-022-08310-4"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ma, Y., Guo, Z., Xia, B., Zhang, Y., Liu, X., Yu, Y., Tang, N., Tong, X., Wang, M., and Ye, X. (2022). Identification of antimicrobial peptides from the human gut microbiome using deep learning. Nat. Biotechnol.","DOI":"10.1038\/s41587-022-01226-0"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-1855-4_1","article-title":"Machine Learning Prediction of Antimicrobial Peptides","volume":"2405","author":"Wang","year":"2022","journal-title":"Methods Mol Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Khabbaz, H., Karimi-Jafari, M.H., Saboury, A.A., and BabaAli, B. (2021). Prediction of antimicrobial peptides toxicity based on their physico-chemical properties using machine learning techniques. BMC Bioinform., 22.","DOI":"10.1186\/s12859-021-04468-y"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2150021","DOI":"10.1142\/S0219720021500219","article-title":"HemoNet: Predicting hemolytic activity of peptides with integrated feature learning","volume":"19","author":"Yaseen","year":"2021","journal-title":"J. Bioinform. Comput. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1038\/s41598-020-67701-3","article-title":"HAPPENN is a novel tool for hemolytic activity prediction for therapeutic peptides which employs neural networks","volume":"10","author":"Timmons","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16581","DOI":"10.1038\/s41598-020-73644-6","article-title":"Machine learning-guided discovery and design of non-hemolytic peptides","volume":"10","author":"Plisson","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"130070","DOI":"10.1016\/j.bbagen.2021.130070","article-title":"Sense the moment: A highly sensitive antimicrobial activity predictor based on hydrophobic moment","volume":"1866","author":"Porto","year":"2022","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_44","unstructured":"(2021, June 01). The Antimicrobial Peptide Database. Available online: https:\/\/aps.unmc.edu."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:59:37Z","timestamp":1760137177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ph15050521"],"URL":"https:\/\/doi.org\/10.3390\/ph15050521","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,24]]}}}